FORLIFE Co.,Ltd.
TTSE:3477848.00
JPY
-1.00
(-0.12%)
ISIN
JP3803020001
Return %
Stock
S&P 500
1Y
-1.17
14.20
3Y
40.40
81.12
5Y
27.90
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Kenji Okumoto
- Full Time Employees
- 115
- Sector
- Consumer durables
- Industry
- Homebuilding
- Address
- 1-14-11 Okurayama Yokohama KN Japan 222-0037
- IPO Date
- Dec 22, 2016
- Website
- forlifeand.com
- Similar Companies
- Business
- FORLIFE Co., Ltd. is a medical device company specializing in the design, development, manufacturing, and distribution of high-quality healthcare products with a core focus on ostomy care, continence care, wound care, and enteral nutrition products. Founded in 1990 and headquartered in Berlin, Germany, the company manufactures specialized medical devices and aids designed to improve the health and quality of life for people with stoma, continence, nutritional, and wound care needs. Its product portfolio includes ostomy care products such as stoma bags and accessories, continence care items, wound dressings, and supportive enteral nutrition products. FORLIFE collaborates closely with patients and healthcare professionals to ensure its products address intimate medical needs effectively. In December 2024, FORLIFE underwent a significant ownership change when it was acquired by European private equity firm Duke Street from GHD GesundHeits GmbH, Germany's largest outpatient health, therapy, and service company. This acquisition included FORLIFE's development and production center in Berlin along with its UK distributor Oakmed. Simultaneously, Duke Street acquired the assets of Trio Healthcare Ltd., a UK-based specialist in stoma care, adding innovative products such as Genii™ stoma bags featuring Sil2 Breathable Silicone Technology® to FORLIFE’s portfolio. This strategic combination aims to create a leading player in the European ostomy care market, enhancing product development capabilities and expanding distribution reach across European markets. FORLIFE operates primarily in Germany and the UK markets and is positioned within the healthcare and medical devices industry, focusing on ostomy, continence, wound care, and nutrition support segments. The company's strategic alliance with Trio Healthcare broadens its product offering and technological innovation, strengthening its market position. The company is part of a portfolio supported by Duke Street, which plans to leverage its investment to drive growth and operational improvements in the healthcare sector with emphasis on product innovation and expanded distribution capacity. This comprehensive operational and strategic profile positions FORLIFE as a specialist healthcare company dedicated to delivering patient-centered medical devices and solutions in the European market. The company's latest changes reflect a notable shift in ownership and an expansion through acquisition, aiming to solidify its leadership in ostomy care and related healthcare products across Europe.